Peripheral T-cell lymphoma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
BV-CHP Variant #01 | — | R 85 959 | 21d | 48.2 mo | — | 8 | R 687 670 PFS proxy | 2 |
GDPT Variant #01 | — | R 6 935 | 21d | — | — | ~6 | ~R 41 608 indirect | — |
CMED Variant #01 | — | R 4 421 | 14d | — | — | ~6 | ~R 26 524 indirect | — |
CHOP-14 (Prednisolone) Variant #01 | — | R 1 048 | 14d | — | — | ~6 | ~R 6 287 indirect | — |
CHOP Variant #20 | — | R 835 | 21d | 15.5 mo | — | 6 | R 5 011 PFS proxy | 3 |
5 of 5 regimens shown